DCAT Value Chain Insights’ Production to Prescription
DCAT
51 episodes
2 weeks ago
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
DCAT Value Chain Insights’ Production to Prescription
14 minutes
4 years ago
Blockbuster Muscle: Small Molecules or Biologics?
Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers) Modality of top-selling productsNew drug approvals: small molecules versus biologicsPotential blockbusters: small molecules and biologicsBiogen’s and Eisai’s aducanumabArgenx’s efgartigimodBristo...
DCAT Value Chain Insights’ Production to Prescription
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
